The American College of Physicians has issued a new clinical guideline naming semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) as preferred first-line drug treatments for adults with obesity, used alongside lifestyle changes. The recommendations were published in Annals of Internal Medicine and ranked other options like phentermine-topiramate, liraglutide, and naltrexone-bupropion below these GLP-1-based therapies. The guideline emphasizes individualized decisions weighing benefits, harms, cost, and patient preferences, and is designated a 'living guideline' to be updated as evidence evolves.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.